{"name":"K. Lieb","slug":"k-lieb","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Escitalopram, venlafaxine","genericName":"Escitalopram, venlafaxine","slug":"escitalopram-venlafaxine","indication":"Major depressive disorder","status":"marketed"},{"name":"Escitalopram, venlafaxine, lithium","genericName":"Escitalopram, venlafaxine, lithium","slug":"escitalopram-venlafaxine-lithium","indication":"Treatment-resistant depression","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Drug use: modafinil","genericName":"Drug use: modafinil","slug":"drug-use-modafinil","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Drug use: modafinil","genericName":"Drug use: modafinil","slug":"drug-use-modafinil","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Escitalopram, venlafaxine","genericName":"Escitalopram, venlafaxine","slug":"escitalopram-venlafaxine","phase":"marketed","mechanism":"This combination of escitalopram (an SSRI) and venlafaxine (an SNRI) increases serotonin and norepinephrine levels in the brain to treat depression and anxiety disorders.","indications":["Major depressive disorder","Generalized anxiety disorder","Panic disorder","Social anxiety disorder"],"catalyst":""},{"name":"Escitalopram, venlafaxine, lithium","genericName":"Escitalopram, venlafaxine, lithium","slug":"escitalopram-venlafaxine-lithium","phase":"marketed","mechanism":"This is a combination therapy using escitalopram (SSRI) and venlafaxine (SNRI) to enhance serotonin and norepinephrine reuptake inhibition, with lithium added for mood stabilization and augmentation.","indications":["Treatment-resistant depression","Bipolar disorder (depression phase)","Major depressive disorder with augmentation"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"marketed":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}